Pub Date : 2026-12-31Epub Date: 2026-09-15DOI: 10.1080/2162402X.2026.2732727
Oliver Kepp, Guido Kroemer
In a recent paper published in Blood Science, Sha et al. report that STAT3 inhibition eliminates multiple myeloma stem-like cells while eliciting hallmarks of immunogenic cell death. These highly intriguing findings connect stemness, integrated stress response, and antitumor immunity, yet in vivo validation remains necessary before this strategy can be considered immunogenic.
{"title":"STAT3 inhibition for the induction of immunogenic cell death in multiple myeloma.","authors":"Oliver Kepp, Guido Kroemer","doi":"10.1080/2162402X.2026.2732727","DOIUrl":"10.1080/2162402X.2026.2732727","url":null,"abstract":"<p><p>In a recent paper published in <i>Blood Science</i>, Sha et al. report that STAT3 inhibition eliminates multiple myeloma stem-like cells while eliciting hallmarks of immunogenic cell death. These highly intriguing findings connect stemness, integrated stress response, and antitumor immunity, yet in vivo validation remains necessary before this strategy can be considered immunogenic.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2732727"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13580471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148971919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-12-31Epub Date: 2026-09-17DOI: 10.1080/2162402X.2026.2706271
Yao Huang, Tao Wu, Wen Yang, Yuan-Yuan Liang, Yun-Fei Sun, Chao-Fan Ma, Ruo Tang, Rui-Ci Liang, Xue-Ting Zheng, Hui-Wen Luo, Cheng-He Ding, Xiao-An Li, Yan Zhou
Lung cancer is characterized by rapid progression and poor prognosis, with 50%-70% of patients presenting local or distant metastasis at diagnosis, among which bone metastasis is the most common type. Radiotherapy is the standard approach for managing cancerous bone metastasis pain. Here, we report the first application of X-ray FLASH radiotherapy (RT) in treating lung cancer bone metastasis in mice. Using an intratibial LLC-luc cell injection model, mice were treated with FLASH RT (94 Gy/s) or conventional RT (CONV RT, 0.1 Gy/s) via a petal accelerator developed by the Institute of Fluid Physics, China Academy of Engineering Physics. The results demonstrated that X-ray FLASH RT and CONV RT exhibited comparable efficacy in suppressing tumor growth, and both may alleviate osteolytic lesions in mice with lung cancer bone metastasis through CD4⁺ T cell-dependent antitumor responses. However, FLASH RT further attenuated bone destruction by inhibiting osteoclastogenesis, remodeling the bone-tumor microenvironment, and reducing tumor invasion, with lower systemic toxicity. Notably, unlike CONV RT, FLASH RT instigates a distinct DNA damage response that drives oxygen depletion, thereby attenuating ROS accumulation. This mechanistic cascade sequentially suppresses cGAS-STING-NF-κB axis activation and dampens the ensuing inflammatory response. In addition, we observed a reduction in Th17 cell differentiation following FLASH RT compared to CONV RT, which may contribute to the differential efficacy of these two radiation modalities in attenuating lung cancer bone metastasis. Collectively, X-ray FLASH RT provides a promising therapeutic strategy for patients with bone metastases.
{"title":"X‑ray FLASH RT inhibits lung cancer bone metastasis via activating CD4⁺ T-cell‑mediated antitumor immunity with modulation of Th17 cell response.","authors":"Yao Huang, Tao Wu, Wen Yang, Yuan-Yuan Liang, Yun-Fei Sun, Chao-Fan Ma, Ruo Tang, Rui-Ci Liang, Xue-Ting Zheng, Hui-Wen Luo, Cheng-He Ding, Xiao-An Li, Yan Zhou","doi":"10.1080/2162402X.2026.2706271","DOIUrl":"10.1080/2162402X.2026.2706271","url":null,"abstract":"<p><p>Lung cancer is characterized by rapid progression and poor prognosis, with 50%-70% of patients presenting local or distant metastasis at diagnosis, among which bone metastasis is the most common type. Radiotherapy is the standard approach for managing cancerous bone metastasis pain. Here, we report the first application of X-ray FLASH radiotherapy (RT) in treating lung cancer bone metastasis in mice. Using an intratibial LLC-luc cell injection model, mice were treated with FLASH RT (94 Gy/s) or conventional RT (CONV RT, 0.1 Gy/s) via a petal accelerator developed by the Institute of Fluid Physics, China Academy of Engineering Physics. The results demonstrated that X-ray FLASH RT and CONV RT exhibited comparable efficacy in suppressing tumor growth, and both may alleviate osteolytic lesions in mice with lung cancer bone metastasis through CD4⁺ T cell-dependent antitumor responses. However, FLASH RT further attenuated bone destruction by inhibiting osteoclastogenesis, remodeling the bone-tumor microenvironment, and reducing tumor invasion, with lower systemic toxicity. Notably, unlike CONV RT, FLASH RT instigates a distinct DNA damage response that drives oxygen depletion, thereby attenuating ROS accumulation. This mechanistic cascade sequentially suppresses cGAS-STING-NF-κB axis activation and dampens the ensuing inflammatory response. In addition, we observed a reduction in Th17 cell differentiation following FLASH RT compared to CONV RT, which may contribute to the differential efficacy of these two radiation modalities in attenuating lung cancer bone metastasis. Collectively, X-ray FLASH RT provides a promising therapeutic strategy for patients with bone metastases.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2706271"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13596902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-12-31Epub Date: 2026-01-18DOI: 10.1080/2162402X.2026.2613561
Lukas Heger, Tomasz Kaszubowski, Lukas Amon, Christian H K Lehmann, Susanne Wingert, José Medina-Echeverz, Joachim Koch, Holger Hackstein, Ariawan Purbojo, Arndt Hartmann, Christoph Alexiou, Robert Cesnjevar, Jens Pahl, Diana Dudziak
Bispecific antibodies are used for the treatment of hematological malignancies as well as solid tumors. One of their main effector mechanisms is the recruitment of effector cells such as CD8+ T cells and CD16A+ NK cells to tumor cells. Bispecific innate cell engagers (ICE®) harnessing CD16A+ NK cells have been shown to induce significant tumor cell lysis in preclinical models, translating to promising signs of clinical activity together with a well-managed safety profile. However, how killing of tumor cells by NK cells influences other innate immune cells in the tumor microenvironment, such as dendritic cells (DCs), instrumental in bridging innate and adaptive tumor immunity, is largely unknown. Thus, we here analyzed whether antibody-dependent cell-mediated cytotoxicity by NK cells affected human DC subpopulations. We could show that killing of tumor cells leads to a strong activation of human conventional DCs type 1 (cDC1), DC2, and DC3 with enhanced expression of co-stimulatory molecules as well as the secretion of proinflammatory cytokines. Further, DC subpopulations as well as surviving tumor cells showed increased expression of the immunoregulatory molecule PD-L1 that is known to dampen T-cell immunity. Nevertheless, ADCC boosted the capacity of cDC1 and DC2 to prime naïve T cell responses but not of DC3. Thus, our data suggests that the therapy with bispecific antibodies targeting NK cells may have the potential to facilitate adaptive antitumor immune responses via activation of cDC1 and DC2.
{"title":"NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells.","authors":"Lukas Heger, Tomasz Kaszubowski, Lukas Amon, Christian H K Lehmann, Susanne Wingert, José Medina-Echeverz, Joachim Koch, Holger Hackstein, Ariawan Purbojo, Arndt Hartmann, Christoph Alexiou, Robert Cesnjevar, Jens Pahl, Diana Dudziak","doi":"10.1080/2162402X.2026.2613561","DOIUrl":"10.1080/2162402X.2026.2613561","url":null,"abstract":"<p><p>Bispecific antibodies are used for the treatment of hematological malignancies as well as solid tumors. One of their main effector mechanisms is the recruitment of effector cells such as CD8<sup>+</sup> T cells and CD16A<sup>+</sup> NK cells to tumor cells. Bispecific innate cell engagers (ICE®) harnessing CD16A<sup>+</sup> NK cells have been shown to induce significant tumor cell lysis in preclinical models, translating to promising signs of clinical activity together with a well-managed safety profile. However, how killing of tumor cells by NK cells influences other innate immune cells in the tumor microenvironment, such as dendritic cells (DCs), instrumental in bridging innate and adaptive tumor immunity, is largely unknown. Thus, we here analyzed whether antibody-dependent cell-mediated cytotoxicity by NK cells affected human DC subpopulations. We could show that killing of tumor cells leads to a strong activation of human conventional DCs type 1 (cDC1), DC2, and DC3 with enhanced expression of co-stimulatory molecules as well as the secretion of proinflammatory cytokines. Further, DC subpopulations as well as surviving tumor cells showed increased expression of the immunoregulatory molecule PD-L1 that is known to dampen T-cell immunity. Nevertheless, ADCC boosted the capacity of cDC1 and DC2 to prime naïve T cell responses but not of DC3. Thus, our data suggests that the therapy with bispecific antibodies targeting NK cells may have the potential to facilitate adaptive antitumor immune responses via activation of cDC1 and DC2.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2613561"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12818816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145999482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-12-31Epub Date: 2026-06-20DOI: 10.1080/2162402X.2026.2671491
Caroline Truntzer, Marion Thibaudin, Paula Anna Bousquet, Morgane Peroz, Valentin Derangère, Alis Ilie, David Rageot, Kjersti Flatmark, Anne Hansen Ree, Sebastian Meltzer, François Ghiringhelli
Background: Colorectal cancer with microsatellite stable (MSS) status is intrinsically resistant to immune checkpoint inhibitor monotherapy targeting PD-1 or PD-L1. However, emerging evidence suggests that chemotherapies may overcome this resistance when combined with immunotherapy.
Methods: We conducted a pooled analysis of individual patient data from two phase II trials evaluating oxaliplatin-based chemotherapy combined with checkpoint inhibitors as first-line treatment for MSS metastatic colorectal cancer. The MEDITREME trial is a single-arm study assessing durvalumab and tremelimumab with oxaliplatin-based chemotherapy, while the METIMMOX trial is a randomized study comparing standard oxaliplatin-based chemotherapy with an alternating regimen of oxaliplatin-based chemotherapy and nivolumab. We compared overall survival (OS), progression-free survival (PFS), and response rates between patients treated with chemotherapy alone versus chemoimmunotherapy, and evaluated the association between these outcomes and transcriptomic and immunoscore data.
Results: A total of 130 patients were included: 38 who received chemotherapy alone and 92 chemoimmunotherapy. The median OS was significantly improved in the chemoimmunotherapy group compared with chemotherapy alone (not reached vs. 15.3 months; HR = 0.58; 95% CI, 0.36-0.96; p = 0.03). The complete response rates were higher with chemoimmunotherapy (14% vs. 5%). No significant differences were observed in PFS. High baseline CD8+ T-cell infiltration was associated with improved outcomes in patients receiving chemoimmunotherapy but not in those treated with chemotherapy alone.
Conclusions: This pooled analysis provides compelling evidence supporting the clinical benefit of first-line chemoimmunotherapy in a subset of patients with MSS mCRC. Baseline CD8+ T-cell infiltration may serve as a predictive biomarker for identifying patients most likely to benefit from this treatment approach.
背景:微卫星稳定(MSS)状态的结直肠癌本质上对靶向PD-1或PD-L1的免疫检查点抑制剂单药治疗具有耐药性。然而,新出现的证据表明,当化疗与免疫治疗联合使用时,可能会克服这种耐药性。方法:我们对来自两项II期试验的个体患者数据进行了汇总分析,评估基于奥沙利铂的化疗联合检查点抑制剂作为MSS转移性结直肠癌的一线治疗。MEDITREME试验是一项评估durvalumab和tremelimumab与奥沙利铂为基础的化疗的单臂研究,而METIMMOX试验是一项比较标准奥沙利铂为基础的化疗与奥沙利铂为基础的化疗和纳武单抗交替方案的随机研究。我们比较了单独化疗与化疗免疫治疗患者的总生存期(OS)、无进展生存期(PFS)和缓解率,并评估了这些结果与转录组学和免疫评分数据之间的关系。结果:共纳入130例患者,其中单独化疗38例,化疗免疫治疗92例。与单独化疗相比,化疗免疫治疗组的中位OS显著改善(未达到vs. 15.3个月;HR = 0.58; 95% CI, 0.36-0.96; p = 0.03)。化疗免疫治疗的完全缓解率更高(14% vs. 5%)。PFS无明显差异。在接受化疗免疫治疗的患者中,高基线CD8+ t细胞浸润与改善预后相关,而在单独化疗的患者中则没有。结论:这项汇总分析提供了令人信服的证据,支持一线化疗免疫治疗对一部分MSS mCRC患者的临床益处。基线CD8+ t细胞浸润可以作为一种预测性生物标志物,用于识别最有可能从这种治疗方法中受益的患者。
{"title":"Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.","authors":"Caroline Truntzer, Marion Thibaudin, Paula Anna Bousquet, Morgane Peroz, Valentin Derangère, Alis Ilie, David Rageot, Kjersti Flatmark, Anne Hansen Ree, Sebastian Meltzer, François Ghiringhelli","doi":"10.1080/2162402X.2026.2671491","DOIUrl":"10.1080/2162402X.2026.2671491","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer with microsatellite stable (MSS) status is intrinsically resistant to immune checkpoint inhibitor monotherapy targeting PD-1 or PD-L1. However, emerging evidence suggests that chemotherapies may overcome this resistance when combined with immunotherapy.</p><p><strong>Methods: </strong>We conducted a pooled analysis of individual patient data from two phase II trials evaluating oxaliplatin-based chemotherapy combined with checkpoint inhibitors as first-line treatment for MSS metastatic colorectal cancer. The MEDITREME trial is a single-arm study assessing durvalumab and tremelimumab with oxaliplatin-based chemotherapy, while the METIMMOX trial is a randomized study comparing standard oxaliplatin-based chemotherapy with an alternating regimen of oxaliplatin-based chemotherapy and nivolumab. We compared overall survival (OS), progression-free survival (PFS), and response rates between patients treated with chemotherapy alone <i>versus</i> chemoimmunotherapy, and evaluated the association between these outcomes and transcriptomic and immunoscore data.</p><p><strong>Results: </strong>A total of 130 patients were included: 38 who received chemotherapy alone and 92 chemoimmunotherapy. The median OS was significantly improved in the chemoimmunotherapy group compared with chemotherapy alone (not reached <i>vs</i>. 15.3 months; HR = 0.58; 95% CI, 0.36-0.96; <i>p</i> = 0.03). The complete response rates were higher with chemoimmunotherapy (14% <i>vs</i>. 5%). No significant differences were observed in PFS. High baseline CD8<sup>+</sup> T-cell infiltration was associated with improved outcomes in patients receiving chemoimmunotherapy but not in those treated with chemotherapy alone.</p><p><strong>Conclusions: </strong>This pooled analysis provides compelling evidence supporting the clinical benefit of first-line chemoimmunotherapy in a subset of patients with MSS mCRC. Baseline CD8<sup>+</sup> T-cell infiltration may serve as a predictive biomarker for identifying patients most likely to benefit from this treatment approach.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2671491"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148297094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sex steroid exposure is a major risk factor for breast cancer initiation and progression through incompletely understood mechanisms. Novel therapeutics for prevention and treatment of estrogen-dependent breast cancer are needed. Cell-cell interactions within the microenvironment contribute to breast cancer progression through extracellular signaling. Here, extracellular proteins were sampled directly from live normal human breast tissue and breast cancers using microdialysis, and 1,101 proteins were quantified. Mechanistic studies were performed in cultured intact normal human breast tissue and mast cells. Findings were validated in vivo using ER+ breast cancer models in immunocompetent and immunocompromised mice and in a zebrafish xenograft model. We identified a breast tissue-specific extracellular protein signature comprising 150 proteins associated with local estradiol (E2) levels, of which several were linked to mast cell biology, including stem cell factor (SCF). Human ER+ breast tumors exhibited increased extracellular SCF levels and higher mast cell density, which was associated with poorer overall survival. In normal human breast tissue, E2 increased mast cell abundance and activity. In vitro, E2 rapidly activated mast cells, an effect blocked by desloratadine. In mouse breast cancer models, E2 increased and fulvestrant reduced mast cell density. In the zebrafish, mast cells promoted ER+ breast cancer growth, which was further enhanced by E2 and abrogated by desloratadine. Overall, our findings identify mast cells as estrogen-responsive stromal mediators and support targeting mast cell-dependent pathways as a potential strategy for the prevention and treatment of estrogen-dependent breast cancer.
{"title":"Estradiol-associated extracellular signaling in the human breast <i>in vivo</i> identifies mast cells as tumor-supportive stromal mediators.","authors":"Annelie Abrahamsson, Xingyue Wang, Wen Zhong, Charlotta Dabrosin","doi":"10.1080/2162402X.2026.2746847","DOIUrl":"10.1080/2162402X.2026.2746847","url":null,"abstract":"<p><p>Sex steroid exposure is a major risk factor for breast cancer initiation and progression through incompletely understood mechanisms. Novel therapeutics for prevention and treatment of estrogen-dependent breast cancer are needed. Cell-cell interactions within the microenvironment contribute to breast cancer progression through extracellular signaling. Here, extracellular proteins were sampled directly from live normal human breast tissue and breast cancers using microdialysis, and 1,101 proteins were quantified. Mechanistic studies were performed in cultured intact normal human breast tissue and mast cells. Findings were validated <i>in vivo</i> using ER<sup>+</sup> breast cancer models in immunocompetent and immunocompromised mice and in a zebrafish xenograft model. We identified a breast tissue-specific extracellular protein signature comprising 150 proteins associated with local estradiol (E2) levels, of which several were linked to mast cell biology, including stem cell factor (SCF). Human ER<sup>+</sup> breast tumors exhibited increased extracellular SCF levels and higher mast cell density, which was associated with poorer overall survival. In normal human breast tissue, E2 increased mast cell abundance and activity. <i>In vitro</i>, E2 rapidly activated mast cells, an effect blocked by desloratadine. In mouse breast cancer models, E2 increased and fulvestrant reduced mast cell density. In the zebrafish, mast cells promoted ER<sup>+</sup> breast cancer growth, which was further enhanced by E2 and abrogated by desloratadine. Overall, our findings identify mast cells as estrogen-responsive stromal mediators and support targeting mast cell-dependent pathways as a potential strategy for the prevention and treatment of estrogen-dependent breast cancer.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2746847"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13671425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149185336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-12-31Epub Date: 2026-10-15DOI: 10.1080/2162402X.2026.2748140
Anne-Laure Mallard de La Varende, Marine Fidelle, Guido Kroemer, Laurence Zitvogel
In a recent paper published in Cancer Cell, we identified subclinical cholestasis as an accessible imprint of gut dysbiosis predicting resistance to immune checkpoint blockade. Our work connects γ-glutamyl transferase, bile-acid remodeling, and MAdCAM-1 loss to compromised antitumor immunity, opening avenues for novel biomarker-guided microbiota interventions.
{"title":"Biomarkers of subclinical cholestasis predict cancer immunotherapy outcomes.","authors":"Anne-Laure Mallard de La Varende, Marine Fidelle, Guido Kroemer, Laurence Zitvogel","doi":"10.1080/2162402X.2026.2748140","DOIUrl":"10.1080/2162402X.2026.2748140","url":null,"abstract":"<p><p>In a recent paper published in Cancer Cell, we identified subclinical cholestasis as an accessible imprint of gut dysbiosis predicting resistance to immune checkpoint blockade. Our work connects <i>γ</i>-glutamyl transferase, bile-acid remodeling, and MAdCAM-1 loss to compromised antitumor immunity, opening avenues for novel biomarker-guided microbiota interventions.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2748140"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13679315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-12-31Epub Date: 2026-10-18DOI: 10.1080/2162402X.2026.2745295
Alexandros Kourtesakis, Dennis Alexander Agardy, Clara Tejido Dierssen, Ling Hai, Dirk Carsten Frieder Hoffmann, Normann Mussnig, Ralph Sinn, Manuel Fischer, Andy Schacht, Michael Breckwoldt, Lukas Bunse, Tim Sauer, Michael Platten, Wolfgang Wick, Tobias Kessler
Chimeric antigen receptor (CAR)-T cell therapy has shown limited efficacy in glioblastoma (GB), largely because of the immunosuppressive tumor microenvironment (TME). We have previously demonstrated that the ligand-based mCD70-directed construct mCAR27 specifically eliminates CD70⁺ GB cells in vitro, and induces durable tumor remission with prolonged survival in a syngeneic model of orthotopic GB. Despite the therapeutic promise of CD70 as a GB CAR-T cell target, the impact of CD70-directed CAR-T cells on the brain tumor immune landscape after target interception remains unexplored. Here, we independently confirmed a tumorigenic role for CD70 in murine GB by performing bulk RNA sequencing and in vivo experiments. Next, we applied single-cell RNA sequencing (scRNAseq) to decipher the transcriptome of GB-infiltrating immune cells in immunocompetent mice bearing CD70+ GB after intratumoral mCAR27 therapy. CAR-T cell treatment expanded adoptively transferred cells and was associated with increased endogenous Cd8⁺ T-cell infiltration, alongside a reduction in immunosuppressive populations, including Tregs and anti-inflammatory M2-like macrophages, but also subsets of dendritic and natural-killer cells. CD70 expression was detected on multiple GB-infiltrating immune subsets, notably Tregs and M2-like macrophages. Transcriptionally, mCAR27-mediated GB remission led to a coordinated downregulation of type-I interferon-stimulated genes and immunosuppressive mediators such as Arg1, Tgfbi, Cd274, Pdcd1lg2 and Lag3, coupled with upregulation of genes involved in inflammatory resolution, findings consistent with attenuation of GB-derived inflammatory stress and immunosuppression. Collectively, we showcase that CD70-directed CAR-T cell therapy remodels the post-treatment immune landscape towards resolution of inflammation and reduced immunosuppression, supporting sustained immune surveillance.
{"title":"Glioblastoma immune landscape remodeling following treatment with CD70-targeted CAR-T cells.","authors":"Alexandros Kourtesakis, Dennis Alexander Agardy, Clara Tejido Dierssen, Ling Hai, Dirk Carsten Frieder Hoffmann, Normann Mussnig, Ralph Sinn, Manuel Fischer, Andy Schacht, Michael Breckwoldt, Lukas Bunse, Tim Sauer, Michael Platten, Wolfgang Wick, Tobias Kessler","doi":"10.1080/2162402X.2026.2745295","DOIUrl":"10.1080/2162402X.2026.2745295","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR)-T cell therapy has shown limited efficacy in glioblastoma (GB), largely because of the immunosuppressive tumor microenvironment (TME). We have previously demonstrated that the ligand-based mCD70-directed construct mCAR27 specifically eliminates CD70⁺ GB cells <i>in vitro</i>, and induces durable tumor remission with prolonged survival in a syngeneic model of orthotopic GB. Despite the therapeutic promise of CD70 as a GB CAR-T cell target, the impact of CD70-directed CAR-T cells on the brain tumor immune landscape after target interception remains unexplored. Here, we independently confirmed a tumorigenic role for CD70 in murine GB by performing bulk RNA sequencing and <i>in vivo</i> experiments. Next, we applied single-cell RNA sequencing (scRNAseq) to decipher the transcriptome of GB-infiltrating immune cells in immunocompetent mice bearing CD70<sup>+</sup> GB after intratumoral mCAR27 therapy. CAR-T cell treatment expanded adoptively transferred cells and was associated with increased endogenous Cd8⁺ T-cell infiltration, alongside a reduction in immunosuppressive populations, including T<sub>regs</sub> and anti-inflammatory M2-like macrophages, but also subsets of dendritic and natural-killer cells. CD70 expression was detected on multiple GB-infiltrating immune subsets, notably T<sub>regs</sub> and M2-like macrophages. Transcriptionally, mCAR27-mediated GB remission led to a coordinated downregulation of type-I interferon-stimulated genes and immunosuppressive mediators such as <i>Arg1</i>, <i>Tgfbi</i>, <i>Cd274</i>, <i>Pdcd1lg2</i> and <i>Lag3</i>, coupled with upregulation of genes involved in inflammatory resolution, findings consistent with attenuation of GB-derived inflammatory stress and immunosuppression. Collectively, we showcase that CD70-directed CAR-T cell therapy remodels the post-treatment immune landscape towards resolution of inflammation and reduced immunosuppression, supporting sustained immune surveillance.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2745295"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13682394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-12-31Epub Date: 2026-04-09DOI: 10.1080/2162402X.2026.2656514
Mirte van der Heijden, James Hugo Armstrong Clubb, Pande Putu Erawijantari, Aki Ronkainen, Victor Arias, Elise Jirovec, Tatiana Kudling, Santeri Artturi Pakola, Nea Ojala, Lyna Haybout, Saru Basnet, Susanna Grönberg-Vähä-Koskela, Sini Karoliina Raatikainen, Otto Hemminki, Anna Kanerva, Dafne Carolina Alves Quixabeira, Victor Cervera-Carrascon, João Manuel Dos Santos, Leo Lahti, Akseli Hemminki
Accumulating evidence implicates the microbiome as an important determinant of clinical outcomes in cancer therapies; however, the role of the microbiome in oncolytic virus therapy remains largely unexplored. We investigated the gut microbiome of cancer patients following treatment with the oncolytic adenovirus igrelimogene litadenorepvec (Ad5/3-E2F-d24-hTNF-IRES-hIL2; TILT-123). Baseline fecal samples from phase I clinical trials (NCT04695327 and NCT05271318) were analyzed using shotgun metagenomic sequencing and compared to treatment outcomes. A higher relative abundance of Alistipes was observed in patients with treatment benefit, while elevated Eggerthella was observed with reduced benefit. These associations were validated in a preclinical mouse model where administration of Alistipes shahii improved the efficacy of adenovirus therapy. In addition, enrichment analysis in patient samples showed a positive correlation between higher relative abundance of Alistipes and elevated short-chain fatty acids in both feces and serum, which in turn revealed higher circulating neutrophil counts. Finally, in a case study, we observed that adenovirus treatment resulted in increased Alistipes relative abundance and reduced Eggerthella relative abundance, indicating that adenovirus therapy may beneficially modulate the microbiome. Overall, our findings reveal a novel association between Alistipes, Eggerthella, and the therapeutic response to oncolytic adenovirus therapy, highlighting their potential as biomarkers or targets for microbiome-based interventions such as pre-, pro-, or postbiotics.
{"title":"<i>Alistipes</i> and <i>Eggerthella</i> shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism.","authors":"Mirte van der Heijden, James Hugo Armstrong Clubb, Pande Putu Erawijantari, Aki Ronkainen, Victor Arias, Elise Jirovec, Tatiana Kudling, Santeri Artturi Pakola, Nea Ojala, Lyna Haybout, Saru Basnet, Susanna Grönberg-Vähä-Koskela, Sini Karoliina Raatikainen, Otto Hemminki, Anna Kanerva, Dafne Carolina Alves Quixabeira, Victor Cervera-Carrascon, João Manuel Dos Santos, Leo Lahti, Akseli Hemminki","doi":"10.1080/2162402X.2026.2656514","DOIUrl":"10.1080/2162402X.2026.2656514","url":null,"abstract":"<p><p>Accumulating evidence implicates the microbiome as an important determinant of clinical outcomes in cancer therapies; however, the role of the microbiome in oncolytic virus therapy remains largely unexplored. We investigated the gut microbiome of cancer patients following treatment with the oncolytic adenovirus igrelimogene litadenorepvec (Ad5/3-E2F-d24-hTNF-IRES-hIL2; TILT-123). Baseline fecal samples from phase I clinical trials (NCT04695327 and NCT05271318) were analyzed using shotgun metagenomic sequencing and compared to treatment outcomes. A higher relative abundance of <i>Alistipes</i> was observed in patients with treatment benefit, while elevated <i>Eggerthella</i> was observed with reduced benefit. These associations were validated in a preclinical mouse model where administration of <i>Alistipes shahii</i> improved the efficacy of adenovirus therapy. In addition, enrichment analysis in patient samples showed a positive correlation between higher relative abundance of <i>Alistipes</i> and elevated short-chain fatty acids in both feces and serum, which in turn revealed higher circulating neutrophil counts. Finally, in a case study, we observed that adenovirus treatment resulted in increased <i>Alistipes</i> relative abundance and reduced <i>Eggerthella</i> relative abundance, indicating that adenovirus therapy may beneficially modulate the microbiome. Overall, our findings reveal a novel association between <i>Alistipes</i>, <i>Eggerthella</i>, and the therapeutic response to oncolytic adenovirus therapy, highlighting their potential as biomarkers or targets for microbiome-based interventions such as pre-, pro-, or postbiotics.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2656514"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13374768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147647081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-12-31Epub Date: 2026-05-07DOI: 10.1080/2162402X.2026.2662708
Jessica C L Notohardjo, Elisa C Toffoli, Tara Muijlwijk, Mari F C M van den Hout, Vinitha Kandiah, Mariette Labots, Rieneke van de Ven, Alfons J M van den Eertwegh, Tanja D de Gruijl
Intradermal delivery of the Toll-like receptor (TLR)-9 agonist agatolimod/CPG7909, prior to sentinel lymph node (SLN) biopsy was previously shown to induce locoregional and systemic immunity, reduce tumor-involved SLN rates, and improve recurrence-free survival in patients with early-stage melanoma. Remarkably, men exhibited superior dendritic cell (DC) maturation. Here, we report on further sex-based differences in the immune response after intradermal administration of CPG7909, which included higher CD80/CD83 expression levels in conventional (c) DC subsets in men's as compared to women's SLN, as well as higher ex-vivo release levels of IL-1β, TNF, and IL-6 (all contributors to cDC activation) and Th1/Th2 cytokines. In an effort to identify a more effective DC-activating therapy for women, we compared the in-vitro effects of CPG7909 with those of the TLR7/8 agonist resiquimod/R848 on SLN single cells from female patients. R848 induced superior cDC subset activation and TNF, IL-6, IL-10, IL-12, IFNγ, and CXCL10 release. Correlation analyses suggested that IFNα, TNF, and IL-6 were key for CPG7909-induced LNR-cDC activation, whereas R848's effect appeared more cytokine-independent. We conclude that combining locally delivered CPG7909 and R848 in early-stage melanoma will ensure full-range DC subset activation and robust pro-inflammatory T-cell responses in melanoma SLN, independent of sex.
{"title":"Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma.","authors":"Jessica C L Notohardjo, Elisa C Toffoli, Tara Muijlwijk, Mari F C M van den Hout, Vinitha Kandiah, Mariette Labots, Rieneke van de Ven, Alfons J M van den Eertwegh, Tanja D de Gruijl","doi":"10.1080/2162402X.2026.2662708","DOIUrl":"10.1080/2162402X.2026.2662708","url":null,"abstract":"<p><p>Intradermal delivery of the Toll-like receptor (TLR)-9 agonist agatolimod/CPG7909, prior to sentinel lymph node (SLN) biopsy was previously shown to induce locoregional and systemic immunity, reduce tumor-involved SLN rates, and improve recurrence-free survival in patients with early-stage melanoma. Remarkably, men exhibited superior dendritic cell (DC) maturation. Here, we report on further sex-based differences in the immune response after intradermal administration of CPG7909, which included higher CD80/CD83 expression levels in conventional (c) DC subsets in men's as compared to women's SLN, as well as higher <i>ex-vivo</i> release levels of IL-1β, TNF, and IL-6 (all contributors to cDC activation) and Th1/Th2 cytokines. In an effort to identify a more effective DC-activating therapy for women, we compared the in-vitro effects of CPG7909 with those of the TLR7/8 agonist resiquimod/R848 on SLN single cells from female patients. R848 induced superior cDC subset activation and TNF, IL-6, IL-10, IL-12, IFNγ, and CXCL10 release. Correlation analyses suggested that IFNα, TNF, and IL-6 were key for CPG7909-induced LNR-cDC activation, whereas R848's effect appeared more cytokine-independent. We conclude that combining locally delivered CPG7909 and R848 in early-stage melanoma will ensure full-range DC subset activation and robust pro-inflammatory T-cell responses in melanoma SLN, independent of sex.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2662708"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13166185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147844759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-12-31Epub Date: 2026-06-05DOI: 10.1080/2162402X.2026.2682058
Tara G Vrooman, Emily R Quarato, Gary Hannon, Noah A Salama, Maggie L Lesch, Angela L Hughson, Vedika S Chandak, Nataliia Vdovichenko, Zhiming Jin, Ronald Lakony, Jian Ye, Sarah L Eckl, Sidney Lesser, Edith M Lord, David C Linehan, Haoming Qiu, Nadia Luheshi, Jim Eyles, Laura M Calvi, Scott A Gerber
Standard of care radiotherapy and chemotherapy have shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). Immunotherapy has emerged as a promising treatment but has been hindered by systemic toxicities. A shift from systemic to localized delivery has reduced adverse effects and improved response rates in various cancers. However, the impact of tumor-targeted therapies on distant tissues, such as the bone marrow, remains underexplored. In a murine model of PDAC, we treated tumors with targeted stereotactic body radiation therapy (SBRT) and intratumoral interleukin-12 mRNA (IL-12). We evaluated tumor, blood, and bone marrow cells for therapy-induced changes over a period of 13 d to 13 months. Our results showed that while SBRT/IL-12 locally eradicated primary tumors, it also induced significant effects in the bone marrow. Early effects included acute lymphopenia in the blood and an immunostimulatory response in the bone marrow, leading to increased hematopoiesis. Long-term effects involved a reduction in hematopoietic stem cells (HSCs) and a shift towards a myeloid lineage, suggesting potential premature aging of the HSC population. These findings highlight the profound impact of localized SBRT/IL-12 therapy on distal bone marrow, emphasizing the need for further investigation into the long-term immunological consequences of localized cancer treatments.
{"title":"Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis.","authors":"Tara G Vrooman, Emily R Quarato, Gary Hannon, Noah A Salama, Maggie L Lesch, Angela L Hughson, Vedika S Chandak, Nataliia Vdovichenko, Zhiming Jin, Ronald Lakony, Jian Ye, Sarah L Eckl, Sidney Lesser, Edith M Lord, David C Linehan, Haoming Qiu, Nadia Luheshi, Jim Eyles, Laura M Calvi, Scott A Gerber","doi":"10.1080/2162402X.2026.2682058","DOIUrl":"10.1080/2162402X.2026.2682058","url":null,"abstract":"<p><p>Standard of care radiotherapy and chemotherapy have shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). Immunotherapy has emerged as a promising treatment but has been hindered by systemic toxicities. A shift from systemic to localized delivery has reduced adverse effects and improved response rates in various cancers. However, the impact of tumor-targeted therapies on distant tissues, such as the bone marrow, remains underexplored. In a murine model of PDAC, we treated tumors with targeted stereotactic body radiation therapy (SBRT) and intratumoral interleukin-12 mRNA (IL-12). We evaluated tumor, blood, and bone marrow cells for therapy-induced changes over a period of 13 d to 13 months. Our results showed that while SBRT/IL-12 locally eradicated primary tumors, it also induced significant effects in the bone marrow. Early effects included acute lymphopenia in the blood and an immunostimulatory response in the bone marrow, leading to increased hematopoiesis. Long-term effects involved a reduction in hematopoietic stem cells (HSCs) and a shift towards a myeloid lineage, suggesting potential premature aging of the HSC population. These findings highlight the profound impact of localized SBRT/IL-12 therapy on distal bone marrow, emphasizing the need for further investigation into the long-term immunological consequences of localized cancer treatments.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2682058"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13245092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}